Quotes 5-day view Delayed Nasdaq
10/16/2020
10/19/2020
10/20/2020
10/21/2020
10/22/2020
Date
94.09(c)
93.92(c)
94.35(c)
87.72(c)
86.36(c)
Last
2 792 475
2 800 200
1 872 146
3 384 553
2 205 906
Volume
+4.10% -0.18% +0.46% -7.03% -1.55% Change
Sales 2020
459 M 544 M 544 M
Net income 2020
-116 M -137 M -137 M
Net cash position 2020
1 286 M 1 523 M 1 523 M
P/E ratio 2020
-112x
Yield 2020
-
Sales 2021
2 866 M 3 394 M 3 394 M
Net income 2021
1 406 M 1 665 M 1 665 M
Net cash position 2021
2 455 M 2 908 M 2 908 M
P/E ratio 2021
15,5x
Yield 2021
-
Capitalization
17 629 M 20 893 M 20 877 M
EV / Sales 2020
35,6x
EV / Sales 2021
5,29x
Nbr of Employees
1 400
Free-Float
92,4%
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer...
Notations Surperformance© of BioNTech SE
Trading Rating : Investor Rating :
All news about BIONTECH SE
News in other languages on BIONTECH SE
Analyst Recommendations on BIONTECH SE
Pfizer vaccine hopes lift world stocks; dollar, gold on the defensive
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BIONTECH SE
Short Term Mid-Term Long Term Trends Bullish Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
9
Average target price
69,03 €
Last Close Price
74,02 €
Spread / Highest target
13,5%
Spread / Average Target
-6,75%
Spread / Lowest Target
-35,6%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
